356 related articles for article (PubMed ID: 24383989)
1. Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease.
Liu Y; Hettinger CL; Zhang D; Rezvani K; Wang X; Wang H
J Neurochem; 2014 May; 129(3):539-47. PubMed ID: 24383989
[TBL] [Abstract][Full Text] [Related]
2. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease.
Bett JS; Cook C; Petrucelli L; Bates GP
PLoS One; 2009; 4(4):e5128. PubMed ID: 19352500
[TBL] [Abstract][Full Text] [Related]
3. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies.
Schipper-Krom S; Juenemann K; Jansen AH; Wiemhoefer A; van den Nieuwendijk R; Smith DL; Hink MA; Bates GP; Overkleeft H; Ovaa H; Reits E
FEBS Lett; 2014 Jan; 588(1):151-9. PubMed ID: 24291262
[TBL] [Abstract][Full Text] [Related]
4. Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin.
Lin L; Jin Z; Tan H; Xu Q; Peng T; Li H
Brain Res; 2016 Jul; 1643():103-12. PubMed ID: 27107943
[TBL] [Abstract][Full Text] [Related]
5. The Differential Profiling of Ubiquitin-Proteasome and Autophagy Systems in Different Tissues before the Onset of Huntington's Disease Models.
Her LS; Lin JY; Fu MH; Chang YF; Li CL; Tang TY; Jhang YL; Chang CY; Shih MC; Cheng PH; Yang SH
Brain Pathol; 2015 Jul; 25(4):481-90. PubMed ID: 25178567
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments.
Li X; Wang CE; Huang S; Xu X; Li XJ; Li H; Li S
Hum Mol Genet; 2010 Jun; 19(12):2445-55. PubMed ID: 20354076
[TBL] [Abstract][Full Text] [Related]
7. Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex.
Li XJ; Zhang YY; Fu YH; Zhang H; Li HX; Li QF; Li HL; Tan RK; Jiang CX; Jiang W; Li ZX; Luo C; Lu BX; Dang YJ
Acta Pharmacol Sin; 2021 Oct; 42(10):1556-1566. PubMed ID: 33495516
[TBL] [Abstract][Full Text] [Related]
8. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
Seo H; Kim W; Isacson O
Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
[TBL] [Abstract][Full Text] [Related]
9. Compartment-Dependent Degradation of Mutant Huntingtin Accounts for Its Preferential Accumulation in Neuronal Processes.
Zhao T; Hong Y; Li S; Li XJ
J Neurosci; 2016 Aug; 36(32):8317-28. PubMed ID: 27511006
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p38 Mitogen-Activated Protein Kinase Ameliorates HAP40 Depletion-Induced Toxicity and Proteasomal Defect in Huntington's Disease Model.
Huang ZN; Chen JM; Huang LC; Fang YH; Her LS
Mol Neurobiol; 2021 Jun; 58(6):2704-2723. PubMed ID: 33492644
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease.
Rippin I; Bonder K; Joseph S; Sarsor A; Vaks L; Eldar-Finkelman H
Neurobiol Dis; 2021 Jul; 154():105336. PubMed ID: 33753290
[TBL] [Abstract][Full Text] [Related]
13. Proteasome activator enhances survival of Huntington's disease neuronal model cells.
Seo H; Sonntag KC; Kim W; Cattaneo E; Isacson O
PLoS One; 2007 Feb; 2(2):e238. PubMed ID: 17327906
[TBL] [Abstract][Full Text] [Related]
14. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease.
Kacher R; Lamazière A; Heck N; Kappes V; Mounier C; Despres G; Dembitskaya Y; Perrin E; Christaller W; Sasidharan Nair S; Messent V; Cartier N; Vanhoutte P; Venance L; Saudou F; Néri C; Caboche J; Betuing S
Brain; 2019 Aug; 142(8):2432-2450. PubMed ID: 31286142
[TBL] [Abstract][Full Text] [Related]
15. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
[TBL] [Abstract][Full Text] [Related]
16. Gedunin Degrades Aggregates of Mutant Huntingtin Protein and Intranuclear Inclusions via the Proteasomal Pathway in Neurons and Fibroblasts from Patients with Huntington's Disease.
Yang W; Xie J; Qiang Q; Li L; Lin X; Ren Y; Ren W; Liu Q; Zhou G; Wei W; Saiyin H; Ma L
Neurosci Bull; 2019 Dec; 35(6):1024-1034. PubMed ID: 31432317
[TBL] [Abstract][Full Text] [Related]
17. Clearance of mutant huntingtin.
Li XJ; Li H; Li S
Autophagy; 2010 Jul; 6(5):663-4. PubMed ID: 20519964
[TBL] [Abstract][Full Text] [Related]
18. Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.
Aladdin A; Király R; Boto P; Regdon Z; Tar K
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717806
[TBL] [Abstract][Full Text] [Related]
19. Defective Mitochondrial Dynamics and Protein Degradation Pathways Underlie Cadmium-Induced Neurotoxicity and Cell Death in Huntington's Disease Striatal Cells.
Kamitsuka PJ; Ghanem MM; Ziar R; McDonald SE; Thomas MG; Kwakye GF
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108341
[TBL] [Abstract][Full Text] [Related]
20. Herp Promotes Degradation of Mutant Huntingtin: Involvement of the Proteasome and Molecular Chaperones.
Luo H; Cao L; Liang X; Du A; Peng T; Li H
Mol Neurobiol; 2018 Oct; 55(10):7652-7668. PubMed ID: 29430620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
